Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume $40.69 -0.77 (-1.86%) (As of 12/17/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Protagonist Therapeutics Short Interest DataProtagonist Therapeutics (PTGX) has a short interest of 3.40 million shares. This marks a 3.03% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.0, indicating that it would take 5.0 days of the average trading volume of 742,068 shares to cover all short positions.Current Short Interest3,400,000 sharesPrevious Short Interest3,300,000 sharesChange Vs. Previous Month+3.03%Dollar Volume Sold Short$148.92 millionShort Interest Ratio5.0 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares59,598,000 sharesPercentage of Shares Shorted5.70%Today's Trading Volume512,279 sharesAverage Trading Volume742,068 sharesToday's Volume Vs. Average69% Short Selling Protagonist Therapeutics? Sign up to receive the latest short interest report for Protagonist Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPTGX Short Interest Over TimePTGX Days to Cover Over TimePTGX Percentage of Float Shorted Over Time Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Protagonist Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20243,400,000 shares $148.92 million +3.0%N/A5 $43.80 11/15/20243,300,000 shares $135.66 million +0.6%N/A4.9 $41.11 10/31/20243,280,000 shares $150.36 million +9.3%N/A5.5 $45.84 10/15/20243,000,000 shares $142.92 million -14.8%N/A4.6 $47.64 9/30/20243,520,000 shares $158.40 million +9.0%N/A5.2 $45.00 9/15/20243,230,000 shares $151.87 million -1.5%N/A3.4 $47.02 Get the Latest News and Ratings for PTGX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20243,280,000 shares $140.68 million +5.8%N/A3.5 $42.89 8/15/20243,100,000 shares $125.83 million +6.9%N/A3.2 $40.59 7/31/20242,900,000 shares $108.58 million -11.0%N/A3.1 $37.44 7/15/20243,260,000 shares $119.81 million +59.8%N/A3.6 $36.75 6/30/20242,040,000 shares $70.69 million -34.6%N/A2.4 $34.65 6/15/20243,120,000 shares $104.18 million -7.7%N/A5.3 $33.39 5/31/20243,380,000 shares $95.15 million -2.6%N/A5.8 $28.15 5/15/20243,470,000 shares $109.20 million -7.0%N/A6.3 $31.47 4/30/20243,730,000 shares $93.66 million +6.0%N/A6.6 $25.11 4/15/20243,520,000 shares $93.56 million +2.3%N/A5.2 $26.58 3/31/20243,440,000 shares $99.52 million +0.6%N/A4.6 $28.93 3/15/20243,420,000 shares $99.11 million +16.3%N/A4.7 $28.98 2/29/20242,940,000 shares $89.32 million +5.8%N/A3.6 $30.38 2/15/20242,780,000 shares $78.48 million +6.5%N/A3.5 $28.23 1/31/20242,610,000 shares $65.28 million +2.4%N/A3.2 $25.01 1/15/20242,550,000 shares $66.05 million +8.5%N/A3.5 $25.90 12/31/20232,350,000 shares $53.89 million -41.0%N/A3.3 $22.93 12/15/20233,980,000 shares $83.86 million +9.3%N/A5.6 $21.07 11/30/20233,640,000 shares $66.28 million -0.3%N/A5.4 $18.21 11/15/20233,650,000 shares $59.46 million -7.4%N/A5.7 $16.29 10/31/20233,940,000 shares $57.29 million +15.5%N/A6 $14.54 10/15/20233,410,000 shares $52.65 million +8.3%N/A5.3 $15.44 9/30/20233,150,000 shares $52.54 million +12.5%N/A4.5 $16.68 9/15/20232,800,000 shares $50.12 million +1.8%N/A3 $17.90 8/31/20232,750,000 shares $54.51 million -9.2%N/A2.8 $19.82 8/15/20233,030,000 shares $56.84 million +2.0%N/A2.8 $18.76 7/31/20232,970,000 shares $57.62 million -10.5%N/A2.7 $19.40 7/15/20233,320,000 shares $70.55 million +4.4%N/A2.8 $21.25 6/30/20233,180,000 shares $87.83 million +18.2%N/A2.7 $27.62 6/15/20232,690,000 shares $77.15 million -12.1%N/A2.5 $28.68 5/31/20233,060,000 shares $79.77 million -15.0%N/A2.5 $26.07 5/15/20233,600,000 shares $93.49 million -3.2%N/A2.2 $25.97 4/30/20233,720,000 shares $84.07 million -14.7%N/A2.2 $22.60 4/15/20234,360,000 shares $81.71 million +0.5%N/A2.5 $18.74Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 3/31/20234,340,000 shares $99.82 million -16.1%N/A2.6 $23.00 3/15/20235,170,000 shares $124.34 million +88.7%N/A3.2 $24.05 2/28/20232,740,000 shares $44.44 million +5.4%6.3%1.9 $16.22 2/15/20232,600,000 shares $42.43 million +2.0%6.0%2.5 $16.32 1/31/20232,550,000 shares $33.89 million +25.6%5.9%2.7 $13.29 1/15/20232,030,000 shares $24.71 million +14.0%4.7%2.4 $12.17 12/30/20221,780,000 shares $19.42 million -4.3%4.1%2.3 $10.91 12/15/20221,860,000 shares $17.73 million +6.9%4.3%2.4 $9.53 11/30/20221,740,000 shares $13.76 million -4.4%4.0%2.2 $7.91 11/15/20221,820,000 shares $14.63 million -7.6%4.2%2.4 $8.04 10/31/20221,970,000 shares $15.96 million -11.7%4.5%2.5 $8.10 10/15/20222,230,000 shares $17.82 million -8.2%5.1%2.6 $7.99 9/30/20222,430,000 shares $20.48 million -13.5%5.6%2.7 $8.43 9/15/20222,810,000 shares $23.24 million +9.3%6.5%2.8 $8.27 8/31/20222,570,000 shares $22.41 million -11.4%5.9%2.4 $8.72 8/15/20222,900,000 shares $32.86 million -31.6%6.7%2.7 $11.33 7/31/20224,240,000 shares $42.19 million -13.1%N/A3.5 $9.95 7/15/20224,880,000 shares $46.16 million +2.3%N/A3.5 $9.46 6/30/20224,770,000 shares $37.73 million +18.4%N/A3.4 $7.91 6/15/20224,030,000 shares $30.14 million +18.9%N/A3 $7.48 5/31/20223,390,000 shares $29.70 million +1.5%N/A2.9 $8.76 5/15/20223,340,000 shares $29.43 million +1.5%N/A2.9 $8.81 4/30/20223,290,000 shares $29.91 million +20.5%N/A3.1 $9.09 4/15/20222,730,000 shares $54.46 million -16.3%N/A3.3 $19.95 3/31/20223,260,000 shares $77.20 million -17.5%N/A4.6 $23.68 3/15/20223,950,000 shares $101.99 million -0.8%N/A5.7 $25.82 2/28/20223,980,000 shares $96.63 million -19.1%N/A5.6 $24.28 2/15/20224,920,000 shares $141.35 million +25.5%N/A7.3 $28.73 1/31/20223,920,000 shares $114.82 million +9.5%N/A6.4 $29.29 1/15/20223,580,000 shares $128.74 million +10.2%N/A5.9 $35.96 12/31/20213,250,000 shares $111.15 million +2.2%N/A2.4 $34.20 12/15/20213,180,000 shares $97.12 million +2.6%N/A2.2 $30.54 11/30/20213,100,000 shares $104.22 million -17.6%7.3%1.6 $33.62 11/15/20213,760,000 shares $134.38 million -15.1%8.8%1.9 $35.74 10/29/20214,430,000 shares $138.04 million +18.5%10.5%2.3 $31.16 10/15/20213,740,000 shares $115.83 million +2.8%8.9%2 $30.97 9/30/20213,640,000 shares $64.50 million +27.3%8.7%2.1 $17.72 9/15/20212,860,000 shares $132.90 million -6.5%6.8%3 $46.47 8/31/20213,060,000 shares $148.41 million -4.4%7.3%7.3 $48.50 8/13/20213,200,000 shares $152.61 million +5.6%7.6%7.3 $47.69 7/30/20213,030,000 shares $149.77 million -11.1%7.3%6.9 $49.43 7/15/20213,410,000 shares $150.93 million -1.7%8.3%8.1 $44.26 6/30/20213,470,000 shares $155.73 million -1.4%8.5%8.5 $44.88 6/15/20213,520,000 shares $134.29 million -3.8%8.6%9.3 $38.15 5/28/20213,660,000 shares $128.50 million -6.2%9.7%11.6 $35.11 5/14/20213,900,000 shares $113.10 million +26.2%N/A12.2 $29.00 4/30/20213,090,000 shares $92.67 million +1.6%N/A9.2 $29.99 4/15/20213,040,000 shares $79.01 million +0.3%N/A9.1 $25.99 3/31/20213,030,000 shares $76.69 million +5.6%N/A8.5 $25.31 3/15/20212,870,000 shares $88.97 million +3.6%N/A6.4 $31.00Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 2/26/20212,770,000 shares $66.45 million -0.4%N/A5.6 $23.99 2/12/20212,780,000 shares $69.75 million +1.5%N/A5.9 $25.09 1/29/20212,740,000 shares $58.25 million -13.6%N/A5.7 $21.26 1/15/20213,170,000 shares $72.43 million -7.9%N/A6.6 $22.85 12/31/20203,440,000 shares $68.77 million +28.4%N/A7.6 $19.99 12/15/20202,680,000 shares $56.07 million +6.8%N/A6.6 $20.92 11/30/20202,510,000 shares $59.86 million -1.6%N/A6.9 $23.85 11/15/20202,550,000 shares $56.64 million No ChangeN/A7.2 $22.21 10/30/20202,550,000 shares $47.15 million -6.9%N/A7.2 $18.49 10/15/20202,740,000 shares $57.46 million -16.5%N/A7.9 $20.97 9/30/20203,280,000 shares $64.12 million +45.8%N/A9.5 $19.55 9/15/20202,250,000 shares $48.74 million +16.0%N/A6.3 $21.66 8/31/20201,940,000 shares $43.46 million +12.1%N/A5.4 $22.40 8/14/20201,730,000 shares $27.14 million +8.8%N/A4.2 $15.69 7/31/20201,590,000 shares $25.01 million +15.2%N/A2.8 $15.73 7/15/20201,380,000 shares $21.51 million +4.6%N/A1.3 $15.59 6/30/20201,320,000 shares $23.31 million -9.6%N/A1.2 $17.66 6/15/20201,460,000 shares $23.51 million +29.2%N/A1.4 $16.10 5/29/20201,130,000 shares $18.69 million -11.7%N/A1.2 $16.54 5/15/20201,280,000 shares $20.74 million +14.3%N/A1.4 $16.20 4/30/20201,120,000 shares $7.56 million -13.9%5.4%1.5 $6.75 4/15/20201,300,000 shares $8.87 million +4.0%6.3%8.6 $6.82 3/31/20201,250,000 shares $8.14 million -8.2%6.1%7.5 $6.51 3/13/20201,362,300 shares $9.47 million +14.5%7.0%9.5 $6.95 2/28/20201,190,000 shares $7.14 million -11.9%6.1%5.7 $6.00 2/14/20201,350,000 shares $10.30 million +3.9%6.9%2.1 $7.63 1/31/20201,300,000 shares $10.82 million +4.8%6.9%2 $8.32 1/15/20201,240,000 shares $10.39 million -20.5%6.5%1.9 $8.38 12/31/20191,560,000 shares $11.73 million +39.3%8.2%2.4 $7.52 PTGX Short Interest - Frequently Asked Questions What is Protagonist Therapeutics' current short interest? Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 3,400,000 shares of PTGX short. Learn More on Protagonist Therapeutics' current short interest. What is a good short interest ratio for Protagonist Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 5.0. Learn More on Protagonist Therapeutics's short interest ratio. Which institutional investors are shorting Protagonist Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Protagonist Therapeutics: Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Protagonist Therapeutics' short interest increasing or decreasing? Protagonist Therapeutics saw a increase in short interest in November. As of November 30th, there was short interest totaling 3,400,000 shares, an increase of 3.0% from the previous total of 3,300,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Protagonist Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Protagonist Therapeutics: Intra-Cellular Therapies, Inc. (1.64%), Roivant Sciences Ltd. (12.55%), Ascendis Pharma A/S (6.22%), Revolution Medicines, Inc. (9.61%), Legend Biotech Co. (13.04%), Nuvalent, Inc. (12.26%), Elanco Animal Health Incorporated (3.15%), Lantheus Holdings, Inc. (6.73%), Blueprint Medicines Co. (6.60%), Cytokinetics, Incorporated (12.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Protagonist Therapeutics stock? Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading down $0.77 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Protagonist Therapeutics? A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further. How often is Protagonist Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Intra-Cellular Therapies Short Interest Roivant Sciences Short Interest Ascendis Pharma A/S Short Interest Revolution Medicines Short Interest Legend Biotech Short Interest Nuvalent Short Interest Elanco Animal Health Short Interest Lantheus Short Interest Blueprint Medicines Short Interest Cytokinetics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTGX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
